TSH: Which Tests to Order Alongside for a Complete Thyroid Workup

What TSH Actually Measures and Why It Is Not Enough Alone

Thyroid-stimulating hormone is produced by the anterior pituitary gland. It tells the thyroid to release T4 and T3, the hormones that regulate metabolism, heart rate, and body temperature. When the thyroid underperforms, TSH rises. When the thyroid overproduces, TSH drops. This feedback loop makes TSH the single most sensitive first-line screening test for thyroid dysfunction, a position endorsed by both the American Thyroid Association (ATA) and the American Association of Clinical Endocrinology (AACE) in their respective guidelines [1][2].

But sensitivity to dysfunction is not the same as diagnostic specificity. TSH tells you that something is off. It does not tell you what is off or why. A TSH of 8.2 mIU/L could mean early Hashimoto thyroiditis, iodine deficiency, recovery from nonthyroidal illness, or a pituitary adenoma producing excess TSH. Each of those scenarios requires a different treatment path, and each demands a different companion test to distinguish it from the others.

The 2012 joint statement from AACE and ATA on hypothyroidism management states: "Serum TSH is the single best screening test for primary thyroid dysfunction in the ambulatory setting, but Free T4 measurement is essential to confirm and classify the abnormality" [1]. That sentence captures the core principle. TSH opens the door. Paired tests walk you through it.

Free T4: The Non-Negotiable Companion

Free T4 should accompany every abnormal TSH result. This is the test that separates subclinical disease from overt disease, a distinction that changes management entirely. A TSH of 12 mIU/L with a normal Free T4 (0.8 to 1.8 ng/dL in most assays) is subclinical hypothyroidism. The same TSH with a Free T4 of 0.4 ng/dL is overt hypothyroidism requiring immediate treatment.

The NHANES III dataset, covering over 13,000 disease-free Americans, established that roughly 4.6% of the U.S. population has subclinical hypothyroidism and 0.3% has overt hypothyroidism [3]. Without Free T4, those two groups are invisible to each other on a lab report. The Colorado Thyroid Disease Prevalence Study (N=25,862) reinforced this, showing that 9.5% of participants had an elevated TSH, but only a fraction had low Free T4 confirming frank disease [4].

Many hospital and reference labs now use "reflex" testing protocols. If TSH falls outside the reference interval (typically 0.4 to 4.0 mIU/L), the lab automatically runs Free T4 on the same blood sample without a second order. Ask your laboratory whether TSH-with-reflex-to-Free-T4 is available. It saves a second draw and accelerates diagnosis.

Free T3: When and Why to Add It

Free T3 is not part of the standard initial thyroid screen. It becomes relevant in three specific clinical scenarios.

First, when TSH is suppressed below 0.1 mIU/L and Free T4 is normal. This pattern can indicate T3 thyrotoxicosis, a condition where the thyroid (or a toxic nodule) overproduces T3 while T4 remains within range. The Endocrine Society's 2016 guidelines on hyperthyroidism recommend measuring both Free T4 and Total or Free T3 when TSH is below 0.1 mIU/L to distinguish T3 thyrotoxicosis from other causes of TSH suppression [5]. T3 thyrotoxicosis accounts for roughly 5% of all hyperthyroid presentations.

Second, when a patient on levothyroxine has a normalized TSH but persistent symptoms of hypothyroidism (fatigue, weight gain, cold intolerance, brain fog). Some patients are poor converters of T4 to T3, particularly those with polymorphisms in the deiodinase type 2 (DIO2) gene. A 2009 study in the Journal of Clinical Endocrinology & Metabolism found that the Thr92Ala DIO2 polymorphism is present in approximately 16% of the general population and may impair intracellular T4-to-T3 conversion [6].

Third, in monitoring patients who take combination T4/T3 therapy or desiccated thyroid extract (Armour Thyroid, NP Thyroid). These preparations deliver exogenous T3, so tracking Free T3 levels is necessary to avoid supraphysiologic T3 peaks.

Outside these situations, ordering Free T3 routinely adds cost without changing management.

TPO Antibodies: Identifying the Autoimmune Driver

Thyroid peroxidase (TPO) antibodies are the primary marker for autoimmune thyroid disease. Hashimoto thyroiditis, the most common cause of hypothyroidism in iodine-sufficient countries, produces elevated TPO antibodies in approximately 90% of cases [7]. The test is most useful when TSH is mildly elevated (4.5 to 10 mIU/L) and you need to determine whether the patient will likely progress to overt hypothyroidism or remain subclinical.

The Whickham Survey, a landmark 20-year prospective cohort study (N=2,779), found that women with both elevated TSH and positive TPO antibodies had an annual risk of progression to overt hypothyroidism of 4.3% per year, compared to 2.6% per year for elevated TSH alone [8]. That difference matters for counseling. A patient with a TSH of 6.5 and positive TPO antibodies has a quantifiably higher chance of eventually needing levothyroxine.

Order TPO antibodies when:

• TSH is in the subclinical range (4.5 to 10 mIU/L) and you need prognostic information
• A family history of autoimmune thyroid disease is present
• The patient has another autoimmune condition (type 1 diabetes, celiac disease, vitiligo)
• Goiter is present on examination
• The patient is planning pregnancy (positive TPO antibodies increase miscarriage risk)

You do not need to repeat TPO antibodies once they are confirmed positive. Antibody titers fluctuate, but seroconversion from positive to negative is rare. One positive result is sufficient for the clinical record.

TSH Receptor Antibodies and Thyroid-Stimulating Immunoglobulins

When hyperthyroidism is confirmed (low TSH, elevated Free T4, or elevated Free T3), the next question is cause. Graves disease accounts for 60 to 80% of hyperthyroidism in iodine-sufficient regions. TSH receptor antibodies (TRAb), also called thyroid-stimulating immunoglobulins (TSI), confirm Graves disease with a sensitivity exceeding 95% and specificity near 99% [9].

Dr. Terry Davies, a past president of the American Thyroid Association, noted in a 2015 review: "TRAb measurement has essentially replaced radioactive iodine uptake as the first-line confirmatory test for Graves disease in many clinical settings" [9]. This shift is significant. A blood test can now replace a nuclear medicine scan in most uncomplicated presentations, reducing cost and radiation exposure.

Order TRAb/TSI when:

• TSH is suppressed with elevated Free T4 or Free T3
• You need to differentiate Graves disease from toxic multinodular goiter or thyroiditis
• A pregnant patient is hyperthyroid (TRAb crosses the placenta and can affect the fetal thyroid)
• You are assessing whether to discontinue antithyroid medication (methimazole, propylthiouracil)

Reverse T3: Limited Utility, Specific Niches

Reverse T3 (rT3) is an inactive metabolite of T4. The body produces more rT3 during acute illness, caloric restriction, and physiologic stress, shunting T4 away from the active T3 pathway. Elevated rT3 is sometimes cited as evidence of "thyroid resistance" or "cellular hypothyroidism" in functional medicine circles, but the Endocrine Society does not endorse routine rT3 measurement for thyroid diagnosis [2].

There is one scenario where rT3 has clear value: distinguishing nonthyroidal illness syndrome (sick euthyroid syndrome) from true central hypothyroidism in critically ill patients. Both conditions show low TSH and low Free T4. A high rT3 points toward nonthyroidal illness; a normal or low rT3 favors genuine hypothalamic-pituitary dysfunction. Outside the ICU, ordering rT3 rarely changes clinical decisions.

Thyroglobulin and Thyroglobulin Antibodies: Cancer Surveillance

Thyroglobulin (Tg) is a protein produced exclusively by thyroid tissue. After total thyroidectomy for differentiated thyroid cancer (papillary or follicular), thyroglobulin serves as a tumor marker. A detectable or rising thyroglobulin level post-surgery suggests residual or recurrent disease. The 2015 ATA guidelines for thyroid cancer management recommend serial thyroglobulin measurements alongside neck ultrasound for long-term surveillance [10].

Thyroglobulin antibodies (TgAb) complicate this picture. Present in roughly 25% of thyroid cancer patients, TgAb can interfere with thyroglobulin immunoassays and produce falsely low readings. For this reason, TgAb must always be ordered alongside thyroglobulin. The 2015 ATA guidelines state: "Serum Tg should be measured by an immunometric assay calibrated against CRM-457, and TgAb should be quantitatively assessed in every sample" [10]. If TgAb is positive, trending the antibody level over time becomes a surrogate marker for disease status.

This pairing (Tg + TgAb) is specific to the cancer surveillance context. It has no role in routine thyroid screening.

Pregnancy: Adjusted Ranges and Additional Tests

Thyroid screening in pregnancy demands different reference ranges and sometimes different paired tests. The 2017 ATA guidelines for thyroid disease in pregnancy recommend using population-based trimester-specific TSH ranges when available [11]. When local references are not established, the guideline suggests an upper TSH limit of approximately 4.0 mIU/L throughout pregnancy, replacing the older recommendation of 2.5 mIU/L in the first trimester.

For pregnant patients with suppressed TSH, TRAb testing is required. Maternal TRAb crosses the placenta freely and can stimulate or block the fetal thyroid. The 2017 ATA guidelines recommend checking TRAb by 22 to 26 weeks of gestation in any woman with active or previously treated Graves disease [11].

TPO antibody status also carries independent significance in pregnancy. A meta-analysis of 31 studies (N=12,126) published in the Journal of Clinical Endocrinology & Metabolism found that TPO-positive euthyroid women had a 2.3-fold increased risk of miscarriage compared to TPO-negative controls [12]. Some clinicians use this information to justify closer TSH monitoring or earlier levothyroxine initiation in TPO-positive women, though this remains an area of ongoing study.

Building Your Paired-Test Strategy by Clinical Scenario

The right combination depends on the clinical question. Here is a practical framework.

Initial screening (asymptomatic patient, routine labs): TSH alone is sufficient as a first step. If TSH returns abnormal, add Free T4.

Suspected hypothyroidism (fatigue, weight gain, cold intolerance): TSH + Free T4 + TPO antibodies. This three-test panel identifies whether dysfunction is present, how severe it is, and whether autoimmunity is driving it.

Suspected hyperthyroidism (weight loss, tremor, palpitations, heat intolerance): TSH + Free T4 + Free T3 + TRAb/TSI. Free T3 catches T3 thyrotoxicosis. TRAb confirms or excludes Graves disease.

Monitoring levothyroxine therapy: TSH + Free T4. Recheck 6 to 8 weeks after any dose change. Add Free T3 only if symptoms persist despite normalized TSH and Free T4.

Post-thyroidectomy cancer surveillance: TSH + Free T4 + thyroglobulin + thyroglobulin antibodies.

Pregnancy with known or suspected thyroid disease: TSH + Free T4 + TPO antibodies (if status unknown) + TRAb (if Graves disease history).

Critically ill hospitalized patient with abnormal thyroid labs: TSH + Free T4 + Free T3 + reverse T3 (to exclude nonthyroidal illness).

This framework covers roughly 95% of clinical presentations. Rare scenarios like TSH-producing pituitary adenomas or thyroid hormone resistance syndromes may require additional specialized testing (alpha-subunit, sex hormone-binding globulin, pituitary MRI), but these affect fewer than 1 in 100,000 people.

How Timing and Medications Affect Your Results

Draw thyroid labs in the morning when possible. TSH follows a circadian rhythm, peaking between midnight and 4 a.m. and reaching its nadir in the late afternoon. A 2005 study in the Journal of Clinical Endocrinology & Metabolism found that afternoon TSH values were up to 50% lower than early morning values in the same individual [13]. This variation can push a borderline TSH result from abnormal to normal depending on the time of the blood draw.

Biotin supplementation above 5 mg daily interferes with many thyroid immunoassays. It can produce falsely low TSH and falsely elevated Free T4, mimicking hyperthyroidism on paper. The FDA issued a safety communication in 2017 advising patients to stop biotin at least 72 hours before thyroid blood work [14].

If a patient takes levothyroxine, draw labs before the morning dose. Taking levothyroxine before the blood draw can transiently spike Free T4 by 15 to 20%, producing a misleadingly high result.